• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Aegis Capital initiated coverage on Can Fite Biofarma with a new price target

    6/24/21 10:10:03 AM ET
    $CANF
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CANF alert in real time by email
    Aegis Capital initiated coverage of Can Fite Biofarma with a rating of Buy and set a new price target of $5.00
    Get the next $CANF alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CANF

    DatePrice TargetRatingAnalyst
    6/24/2021$5.00Buy
    Aegis Capital
    More analyst ratings

    $CANF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Can-Fite Reports H1 2025 Financial Results and Clinical Update

    Ramat Gan, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced financial results and clinical updates for H1, 2025. Clinical & Development Milestones Achieved Namodenoson Drug Candidate – Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone The Phase 2a study (NCT06387342) is a multicenter, open-label trial enrolling patients with advanced pancreatic adenocarcinoma whose disease has progressed following at least one line of prior therapy. The study is eva

    8/28/25 8:47:00 AM ET
    $CANF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone

    Primary endpoint is safety; Namodenoson continues to demonstrate a favorable safety profile Ramat Gan, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced that it achieved the over 50% enrollment milestone in its Phase 2a trial of Namodenoson for pancreatic cancer. The Phase 2a study is a multicenter, open-label trial enrolling patients with advanced pancreatic adenocarcinoma whose disease has progressed following at least one line of prior therapy. The study is evaluating the safet

    7/30/25 7:04:46 AM ET
    $CANF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Can-Fite Announces Up To $15.0 Million Public Offering

    $5.0 million upfront with up to an additional $10.0 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants RAMAT GAN, Israel, July 28, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF) ("Can-Fite" or the "Company"), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced the pricing of a public offering with a single institutional investor of 8,333,333 of the Company's American Depositary Shares ("ADSs") (or pre-funded warrants in lieu thereof), together with short-term warrants to purchase up to 16,666,666 ADSs at

    7/28/25 12:24:30 PM ET
    $CANF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CANF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aegis Capital initiated coverage on Can Fite Biofarma with a new price target

    Aegis Capital initiated coverage of Can Fite Biofarma with a rating of Buy and set a new price target of $5.00

    6/24/21 10:10:03 AM ET
    $CANF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CANF
    Financials

    Live finance-specific insights

    View All

    60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / November 22, 2024 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) and Can-Fite BioPharma Ltd. (NYSE:CANF)(TASE:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, November 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:SXTP: https://www.redchip.com/assets/access/sxtp_accessCANF: https://www.redchip.com/assets/access/canf_accessIn an exclusive interview, Geoffrey Dow, CEO and President of 60 Degrees Pharmaceuticals, appears on the RedChip Small Stocks Big Money™ show on

    11/22/24 9:00:00 AM ET
    $CANF
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / August 9, 2024 / RedChip Companies will air interviews with OS Therapies Inc. (NYSE:OSTX) and Can-Fite BioPharma Ltd. (NYSE:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 10, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:OS Therapies: https://www.redchip.com/assets/access/ostx_accessCan-Fite: https://www.redchip.com/assets/access/canf_accessIn an exclusive interview, Paul Romness, Chairman and CEO of OS Therapies, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate

    8/9/24 9:00:00 AM ET
    $CANF
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / May 10, 2024 / RedChip Companies will air interviews with Can-Fite BioPharma Ltd. (NYSE:CANF) and Nutriband Inc. (NASDAQ:NTRB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, May 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Can-Fite: https://www.redchip.com/assets/access/canf_accessNutriband: https://www.redchip.com/assets/access/ntrb_accessIn an exclusive interview, Pnina Fishman, Executive Chairperson and Chief Scientific Officer of Can-Fite BioPharma, appears on the RedChip Small Stocks, Big Money™ show on Blo

    5/10/24 9:00:00 AM ET
    $CANF
    $NTRB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    $CANF
    SEC Filings

    View All

    SEC Form POS AM filed by Can-Fite Biopharma Ltd Sponsored ADR (Israel)

    POS AM - Can-Fite BioPharma Ltd. (0001536196) (Filer)

    9/8/25 5:27:27 PM ET
    $CANF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form POS AM filed by Can-Fite Biopharma Ltd Sponsored ADR (Israel)

    POS AM - Can-Fite BioPharma Ltd. (0001536196) (Filer)

    9/8/25 5:24:41 PM ET
    $CANF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form POS AM filed by Can-Fite Biopharma Ltd Sponsored ADR (Israel)

    POS AM - Can-Fite BioPharma Ltd. (0001536196) (Filer)

    9/8/25 10:25:13 AM ET
    $CANF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CANF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Can-Fite Biopharma Ltd Sponsored ADR (Israel)

    SC 13G/A - Can-Fite BioPharma Ltd. (0001536196) (Subject)

    11/14/24 4:48:49 PM ET
    $CANF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Can-Fite Biopharma Ltd Sponsored ADR (Israel)

    SC 13G - Can-Fite BioPharma Ltd. (0001536196) (Subject)

    2/14/24 3:32:17 PM ET
    $CANF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Can-Fite Biopharma Ltd Sponsored ADR (Israel) (Amendment)

    SC 13G/A - Can-Fite BioPharma Ltd. (0001536196) (Subject)

    2/14/22 3:23:08 PM ET
    $CANF
    Biotechnology: Pharmaceutical Preparations
    Health Care